As of Friday close, Sangamo Therapeutics Inc.’s (NASDAQ:SGMO) stock traded at $0.92. The average number of shares traded per day over the past five days has been 1,450,320 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.1634 fall in that time frame. In the last twenty days, the average volume was 1,252,100, while in the previous 50 days, it was 2,108,160.
Since last month, SGMO stock retreated -35.68%. Shares of the company fell to $0.9000 on 08/18/23, the lowest level in the past month. A 52-week high of $6.07 was reached on 01/13/23 after having rallying from a 52-week low of $0.90. Since the beginning of this year, SGMO’s stock price has dropped by -70.81% or -$2.2234, and marked a new high 6 times. However, the stock has declined by -84.90% since its 52-week high.
SGMO stock investors should be aware that Sangamo Therapeutics Inc. (SGMO) stock had its last reported insider trading activity 354 days ago on Aug 30. BIOGEN INC., the 10% Owner of the company, disposed of 100,000 shares for $5.27 on Aug 30. It resulted in a $526,520 divestment by the insider. BIOGEN INC. sold 400,000 shares at an average price of $5.33 on Aug 29. The insider now owns 23,752,466 shares following the transaction.
Valuation Metrics
The stock’s beta is 1.14. Besides these, the trailing price-to-sales (P/S) ratio of 0.72, the price-to-book (PB) ratio of 0.68.
Financial Health
In the recent quarter, Sangamo Therapeutics Inc.’s quick ratio stood at 3.00, while its current ratio was 3.00, showing that the company is able to pay off its debt. In the recent year, EBITDA margin amounted to -169.97%, whereas operating margins totaled -98.80%. Based on annual data, SGMO earned $312.58 million in gross profit and brought in $111.3 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -68.40%. Return on equity (ROE) for the past 12 months was -67.70%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. SGMO’s revenue fell -329.53% to $157.96 million during the quarter, while net income inched up to $6.84 million. During the quarter, the company generated -$66.86 million in EBITDA. The liabilities of Sangamo Therapeutics Inc. were 91.43 million at the end of its most recent quarter, and its total debt was $36.37 million. The value of shareholders’ equity is $177.11 million.
Technical Picture
This quick technical analysis looks at Sangamo Therapeutics Inc.’s (SGMO) price momentum. With a historical volatility rate of 54.99%, the RSI 9-day stood at 18.96% on 18 August.
With respect to its five-day moving average, the current Sangamo Therapeutics Inc. price is down by -15.13% percent or -$0.1634. At present, SGMO shares trade -34.06% below its 20-day simple moving average and -47.32% percent below its 100-day simple moving average. However, the stock is currently trading approximately -29.49% below its SMA50 and -79.12% below its SMA200.
Stochastic coefficient K was 3.46% and Stochastic coefficient D was 5.68%, while ATR was 0.0744. Given the Stochastic reading of 3.69% for the 14-day period, the RSI (14) reading has been calculated as 27.08%. As of today, the MACD Oscillator reading stands at -0.0951, while the 14-day reading stands at -0.1659.
Analyst Ratings
Sangamo Therapeutics Inc. downgraded its rating on Sangamo Therapeutics Inc. (NASDAQ: SGMO) to an Underperform in a note to investors on April 28, 2023. The analysts firm previously had a Neutral rating on the stock.Sangamo Therapeutics Inc. (SGMO) has been rated Overweight by analysts. According to 0 brokerage firms, SGMO is a sell, and 2 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate Sangamo Therapeutics Inc. stock as buy, with 7 recommending it as overweight.
